These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10249123)

  • 21. Prescription drug coverage: insurance or prepayment?
    Rucker TD
    Pharm Manage Comb Am J Pharm; 1979; 151(4):171-3. PubMed ID: 493376
    [No Abstract]   [Full Text] [Related]  

  • 22. Medicare prescription drug coverage (part D): challenges and opportunities.
    Witten B
    Nephrol News Issues; 2006 Aug; 20(9):14-6, 18. PubMed ID: 16916055
    [No Abstract]   [Full Text] [Related]  

  • 23. The new Medicare Advantage a disadvantage for providers?
    O'Hare PK
    Healthc Financ Manage; 2004 Mar; 58(3):36-40. PubMed ID: 15029797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What's at stake.
    Gordon JR; Maule CJ
    CPJ; 1989 Feb; 122(2):74-6, 78. PubMed ID: 10292087
    [No Abstract]   [Full Text] [Related]  

  • 25. Capitation for pharmacy services: rationale, findings, and future plans.
    Lipson DP; Yesalis CE; Norwood GJ
    Med Mark Media; 1980 Oct; 15(10):25-32. PubMed ID: 10249119
    [No Abstract]   [Full Text] [Related]  

  • 26. The piggyback dilemma.
    Tanner DJ
    Hosp Pharm; 1978 Jun; 13(6):326. PubMed ID: 10307644
    [No Abstract]   [Full Text] [Related]  

  • 27. Controlling pharmacy costs in the NC Medicaid program.
    Dobson LA
    N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
    [No Abstract]   [Full Text] [Related]  

  • 28. Third-Party underpayments.
    Miller WF
    Am Pharm; 1979 Aug; 19(9):4. PubMed ID: 506918
    [No Abstract]   [Full Text] [Related]  

  • 29. 25th annual prescription survey: Albany College of Pharmacy of Union University.
    DeNuzzo RV
    Med Mark Media; 1981 Apr; 16(4):31-2, 34-51. PubMed ID: 10250762
    [No Abstract]   [Full Text] [Related]  

  • 30. Reimbursement for drugs under third-party programs.
    Palumbo FB
    Pharm Res; 1990 Jan; 7(1):108-9. PubMed ID: 2405381
    [No Abstract]   [Full Text] [Related]  

  • 31. [Changes of drug reimbursement expenses incurred by National Health Fund in Silesian voivodeship in the period of 1999-2004].
    Swistak P; Dzielicki M; Janiec R; Błońska-Fajfrowska B
    Wiad Lek; 2005; 58(9-10):495-9. PubMed ID: 16529058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2003.
    Johnson P
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-25. PubMed ID: 14969256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating third-party prescription program contracts.
    Fink JL
    Pharm Manage Comb Am J Pharm; 1979; 151(3):114-9. PubMed ID: 482397
    [No Abstract]   [Full Text] [Related]  

  • 34. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals.
    Carlson JJ; Garrison LP; Sullivan SD
    J Manag Care Pharm; 2009 Oct; 15(8):683-7. PubMed ID: 19803557
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescription benefit design: perspectives, reimbursement issues, and future trends.
    Owens G; Balfour D; Cohen J; Cohen S; Jacobs M; Lease M; Ratnesar R; Schaecher KL; Wilcox DE
    Am J Manag Care; 2004 Oct; 10(13 Suppl):S420-3. PubMed ID: 15622873
    [No Abstract]   [Full Text] [Related]  

  • 36. Third-party reimbursement. How did we get where we are today?
    Gagnon JP
    Am Pharm; 1980 Dec; NS20(12):31-8. PubMed ID: 7457361
    [No Abstract]   [Full Text] [Related]  

  • 37. Preparing for a third-party audit.
    Fink JL
    Am Pharm; 1983 Aug; NS23(8):49-51. PubMed ID: 6624640
    [No Abstract]   [Full Text] [Related]  

  • 38. West Virginia's Rx for drug costs: West Virginia's new prescription drug program is being called "the mouse that roared".
    Kent C
    State Legis; 2005 Feb; 32(2):23. PubMed ID: 15704275
    [No Abstract]   [Full Text] [Related]  

  • 39. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The forgotten component of third party reimbursement. Net profit.
    Proctor KA; Kirk KW
    Am Pharm; 1987 Apr; NS27(4):52-5. PubMed ID: 3591638
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.